- Vonoprazan is a potassium-competitive acid blocker (P-CAB) that reversibly inhibits the H+/K+ ATPase enzyme in the stomach’s parietal cells. Unlike traditional PPIs, it does not require acid activation and provides more rapid and sustained acid suppression through its direct competitive binding to the proton pump.
- The medication is primarily indicated for acid-related disorders, including erosive esophagitis, gastroesophageal reflux disease (GERD), and gastric/duodenal ulcers. Its rapid onset of action and consistent acid suppression throughout the day make it particularly effective in controlling symptoms like heartburn and acid reflux.
- Vonoprazan has shown superior efficacy in H. pylori eradication therapy when compared to conventional PPIs. When combined with antimicrobial agents, its strong and stable acid-suppressing effect creates an optimal environment for antibiotic activity, resulting in higher eradication rates, particularly in cases of clarithromycin-resistant H. pylori strains.
Disclaimer: While we strive to continuously improve and update our content, we cannot guarantee its accuracy or completeness. Please note that the content is continuously evolving, and updates may not reflect the most current information. The information contained on this website is for general informational purposes only and should not be considered as professional advice. We disclaim any liability for any loss or damage resulting from the use of the information provided herein. Always consult qualified professionals for specific guidance and verify any critical information before relying on it. Read more
